Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

-------------- 13,762 19,553 ------------------------------------------------------------------------- Loss from operations (7,340) (13,442) ------------------------------------------------------------------------- Other income Interest income 58 154 Foreign exchange gain 1,402 900 ------------------------------------------------------------------------- 1,460 1,054 ------------------------------------------------------------------------- Net loss for the period (5,880) (12,388) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Net loss per share Basic and diluted (0.09) (0.23) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of shares Basic and diluted 63,089,954 53,187,470 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Interim Consolidated Balance Sheet Information (in thousands) (unaudited) ------------------------------------------------------------------------- As at As at March 31, December 31, 2010 2009 ------------------------------------------------------------------------- ----------------------------
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
(Date:8/21/2014)... Ontotext S4 , The Self Service ... Now the same enterprise hardened text mining, Linked ... data is available to start-ups and mid-size businesses at ... that do not have resources to evaluate and prototype ... since there is no need for on premise hardware ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... Clinical Trial Programs Funded Through 2009, SAN ... and Ottawa, Ontario), a clinical stage biopharmaceutical company,developing ... today announced the closing of a financing transaction ... target of $8 million USD.,The offering was completed ...
... 9 InNexus,Biotechnology Inc., (TSX: IXS.V, OTC Bulletin ... commercializing the next,generation of monoclonal antibodies based on ... to its Board of Directors., Mr. Warden ... Coleman, L.L.P.,In his 23 years of practice, he ...
... Rib-X Pharmaceuticals, Inc.,("Rib-X" or the "Company"), ... development of novel antibiotics for the treatment ... its,Clinical Advisory Board. The Board, comprised of ... counsel on matters related to the,Company,s clinical ...
Cached Biology Technology:Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 2Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 3InNexus Biotechnology Strengthens Patent Team With New Leadership 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 3
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/20/2014)... John and Rebecca Moores Professor of Biology and Biochemistry at ... the International Society for the Study of the Origin of ... two from the U.S., one from France and one ... elected every three years, and 36 have been named since ... countries, the ISSOL includes researchers from disciplines as varied as ...
(Date:8/20/2014)... Tbingen, Arizona State University, the Wellcome Trust Sanger Institute ... TPH) isolated Mycobacterium pinnipedii from skeletons found ... The pathogen is a relative of the TB bacterium ... humans today. These researchers assume that seals carried the ... to sea lions was unexpected" comments Sebastien Gagneux, from ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2UH professor named fellow by International Astrobiology Society 2
... today at the American College of Neuropsychopharmacology's Annual Meeting ... age 90 with preserved cognition. The study, which ... conducted at the University of Pittsburgh, is among the ... , "While successful aging has been defined in ...
... the world would help stave off an imminent global ... the Proceedings of the National Academy of Sciences ( ... 52 member organizations of the Alliance for Zero Extinction ... threatened with imminent extinction, each of which is in ...
... at the University of Colorado at Boulder that can ... patient samples within hours may help world health officials ... on the new technology by the Centers for Disease ... Chip can determine the genetic make-up of types and ...
Cached Biology News:New research examines genetics of successful aging 2Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy 2New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 2New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 3New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 4
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
...
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
15(S)-HETE-d8 is used as an internal standard for the quantification of 15(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: